Our findings provide a promising therapeutic strategy to prevent metastasis in a subset of cancer patients who are positive for the Rab22a1–38 fusion gene(s), as the Rab22a1–38 portion governs the metastasis-promoting function of Rab22a-NeoFs. This evidence concerns the gene RAB22A and cancer.